초록 ▼

The invention relates to a stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject. The invention is characterized in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein mole

The invention relates to a stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject. The invention is characterized in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond.

대표청구항 ▼

1. A stable immunogenic product for inducing antibodies risen against IFNα protein in a subject comprising protein immunogenic heterocomplexes consisting of associations between (i) IFNα molecules and (ii)KLH protein carrier molecules wherein more than 1% and less than 40% of the IFNα molecules are

1. A stable immunogenic product for inducing antibodies risen against IFNα protein in a subject comprising protein immunogenic heterocomplexes consisting of associations between (i) IFNα molecules and (ii)KLH protein carrier molecules wherein more than 1% and less than 40% of the IFNα molecules are covalently linked to the KLH protein carrier molecules (ii), and more than 60% of IFNα molecules are non-covalently associated with the protein carrier molecules (ii), and wherein said stable immunogenic product is produced by a process comprising the following steps: a. incubating the IFNα proteins and KLH protein carrier molecules in a molar ratio IFNα:KLH ranging from 10:1 to 50:1 in the presence of glutaraldehyde to produce immunogenic heterocomplexes;b. removing excess glutaraldehyde;c. stabilizing the immunogenic heterocomplexes with formaldehyde;d. adding glycine to block the reaction with formaldehyde in step c);e. performing a dialysis of the product obtained at step d); andf. collecting the product comprising immunogenic heterocomplexes prepared at step e). 2. The stable immunogenic product according to claim 1, wherein each heterocomplex comprises (i) a plurality of IFNα molecules associated to (ii) a carrier protein molecule. 3. The stable immunogenic product according to claim 2 wherein for each immunogenic heterocomplex, the plurality of antigenic proteins (i) is made up of a plurality of specimens of a single IFNα molecules. 4. The stable immunogenic product according to claim 1 comprising 20 to 40 antigenic proteins (i) for one carrier protein molecule (ii). 5. The stable immunogenic product of claim 1 wherein in step a) the IFNα molecules and the carrier protein molecules are incubated in the presence of glutaraldehyde at a final concentration from 0.002 M to 0.03 M for 20 minutes to 60 minutes. 6. A composition comprising the immunogenic product according to claim 1. 7. A pharmaceutical composition comprising the immunogenic product according to claim 1 in association with one or more physiologically compatible excipients. 8. An immunogenic composition comprising the immunogenic product according to claim 1 in association with one or more physiologically compatible excipients. 9. The immunogenic composition according to claim 8, further comprising a mucosal or a systemic immunity immunoadjuvant.